(Q24602567)

English

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

scientific article

In more languages

Statements

scholarly article

0 references

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate (English)

0 references

multiple sclerosis

0 references

Jana Lízrová Preiningerová

1 reference

ORCID Public Data File 2021

author name string

C Ford

1

0 references

A D Goodman

2

0 references

K Johnson

3

0 references

N Kachuck

4

0 references

J W Lindsey

5

0 references

R Lisak

6

0 references

C Luzzio

7

0 references

L Myers

8

0 references

H Panitch

9

0 references

J Preiningerova

10

0 references

A Pruitt

11

0 references

J Rose

12

0 references

H Rus

13

0 references

J Wolinsky

14

0 references

language of work or name

0 references

publication date

March 2010

0 references

Multiple Sclerosis Journal

0 references

16

0 references

3

0 references

342-50

0 references

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

7 April 2017

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

7 April 2017

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

7 April 2017

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

7 April 2017

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

27 September 2017

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

27 September 2017

Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

27 September 2017

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

27 September 2017

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850588

30 May 2018

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

1 reference

https://api.crossref.org/works/10.1177%2F1352458509358088

21 January 2018

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20106943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20106943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/20106943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20106943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20106943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1352458509358088

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24602567&oldid=1959072025"